Home>Topics>Companies>Novo Nordisk

Novo Nordisk

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. What To Watch For As Orexigen's Launch Approaches

    Headlines

    Thu, 16 Oct 2014

    companies with FDA approved anti-obesity drugs on the market. Other players looking to enter the space are Novo Nordisk (NYSE: NVO ) and Zafgen (NASDAQ: ZFGN ). All will have a presence at Obesity Complete Story »

  2. Novo Nordisk's NNIT to announce IPO next week - Berlingske daily

    Headlines

    Wed, 15 Oct 2014

    COPENHAGEN, Oct 15 (Reuters) - NNIT, the information technology unit of Danish pharmaceutical company Novo Nordisk , is expected to announce plans for an initial public offering (IPO) on the Nasdaq Copenhagen exchange next week, daily Berlingske reported on Wednesday.

  3. Sanofi Vs. MannKind - Afrezza Is Better For Sanofi

    Headlines

    Fri, 26 Sep 2014

    Pg. 25) " and the ever-present global effort to improve healthcare standards. The Diabetes Market Also from the Novo - Nordisk 2013 annual report: 382 million people with diabetes worldwide Only 45-50 million insulin users $40 billion Diabetes

  4. 2 Reasons Why Eli Lilly's New Diabetes Drug Might Not Become A Blockbuster

    Headlines

    Thu, 25 Sep 2014

    blood sugar levels. The GLP-1 market is dominated by Novo Nordisk 's Victoza, which generated sales of $2.07 billion ..... billion. Trulicity has been found as non-inferior to Novo Nordisk 's standard GLP-1 therapy, Victoza, in head-to

  5. EC clears Xultophy

    Headlines

    Fri, 19 Sep 2014

    The European Commission approves Novo Nordisk 's (NYSE: NVO ) Xultophy for the treatment of adult patients with ..... degludec ( Tresiba ) and liraglutide ( Victoza ). Novo plans to launch the product in Europe in 1H 2015

  6. Novo's Ryzodeg provides glycemic control with fewer injections but fails in Phase 3 trial

    Headlines

    Thu, 18 Sep 2014

    In a Phase 3b clinical trial , Novo Nordisk 's (NYSE: NVO ) Ryzodeg (insulin degludec/insulin aspart) administered twice daily provided successful glycemic control with fewer injections

  7. Novo's Ryzodeg effective in type 2 diabetes treatment -study

    Headlines

    Thu, 18 Sep 2014

    COPENHAGEN, Sept 18 (Reuters) - Novo Nordisk 's type 2 diabetes treatment Ryzodeg has proved effective in providing good blood sugar control with fewer injections than a so-called basal-bolus treatment, according to new data from a late-stage study.

  8. Study shows Novo's new diabetes drug effective and safe for children

    Headlines

    Tue, 16 Sep 2014

    COPENHAGEN, Sept 16 (Reuters) - Novo Nordisk 's new long-acting insulin Tresiba has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according...

  9. Novo Gets Positive Vote From FDA For Anti-Obesity Treatment - Still A Long Road Ahead

    Headlines

    Fri, 12 Sep 2014

    By Spencer Osborne : Novo Nordisk (NYSE: NVO ) received good news earlier this week in its quest to get an obesity indication for its drug Saxenda. The drug is a different

  10. UPDATE 3-U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity

    Headlines

    Fri, 12 Sep 2014

    * Novo 's Saxenda safe, effective enough for approval - FDA panel

« Prev12345Next »
Content Partners